Drug Profile
Research programme: therapeutics - RELIEF THERAPEUTICS Holding
Alternative Names: DasKloster 0014-01; DasKloster 0039-01; DasKloster 0080-01; DasKloster 0182-01; DasKloster 0228-01; DasKloster 0249-01; DasKloster 0274-01; DasKloster 0501-01; DK 0051; Gonadorelin - RELIEF THERAPEUTICS; Octreotide - RELIEF THERAPEUTICS; Proadrenomedullin - RELIEF THERAPEUTICS; Valorphin - RELIEF THERAPEUTICSLatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Class Antibacterials; Antineoplastics; Antituberculars; Peptides; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Liver cancer; Lung disorders; Lymphoproliferative disorders; Pseudomonal infections; Scleroderma; Tuberculosis
Most Recent Events
- 24 Feb 2023 Discontinued - Preclinical for Tuberculosis in Switzerland (unspecified route) (RELIEF THERAPEUTICS pipeline, February 2023)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Tuberculosis in Switzerland
- 22 Sep 2016 Preclinical development is ongoing for Tuberculosis (RELIEF THERAPEUTICS pipeline, September 2016)